An inactivated oil-emulsion fowl Adenovirus serotype 4 vaccine provides broad cross-protection against various serotypes of fowl Adenovirus

• We investigated protective efficacy of FAdV-4 vaccine against other serotypes.
• To test that efficacy we conducted serological study and animal challenge study.
• That vaccine provided broad cross-protection efficacy to vaccinated bird and progenies.

The number of clinical cases of inclusion body hepatitis (IBH) and hydropericardium-hepatitis syndrome (HHS) has been increasing, resulting in considerable economic losses in many countries. Currently, only fowl Adenovirus (FAdV) serotype 4 (FAdV-4) has been reported as the causative agent of HHS, whereas IBH can be caused by all 12 serotypes of FAdV. For protection against HHS, various live and killed FAdV serotype 4 vaccines have been developed. However, there is a concern whether these vaccines composed of FAdV-4 alone could provide protection against IBH, which is caused by other serotypes of virulent FAdVs. To date, there have been no reports evaluating the protective efficacy of the FAdV-4 vaccine against other serotypes of FAdV. Thus, we investigated the cross-protection efficacy of an inactivated oil-emulsion FAdV-4 vaccine against various serotypes of FAdV field isolates. Our study demonstrated that the inactivated oil-emulsion FAdV-4 vaccine could provide broad cross-protection against various serotypes of FAdV in not only vaccinated birds, but also the progenies of vaccinated breeder. Therefore, we conclude that the inactivated oil-emulsion FAdV-4 vaccine could be effective in preventing the spread of various other serotypes of FAdV as well as FAdV-4 infection in the poultry industry.